We read with interest the recent article in Nature Medicine describing the influence of variation in CCL3L1 copy number and CCR5 genotype on immune recovery during highly active antiretroviral therapy (HAART) in HIV-1-infected individuals 1 . The chemotactic cytokine CCL3L1 (encoding the macrophage inflammatory protein-1αP (MIP-1αP) protein) is a potent ligand for the HIV-1 co-receptor CCR5, which is essential for viral entry into human host cells 2 . The recent study is part of a series that began in 2005 with a paper reporting effects of CCL3L1 copy number variation on HIV-1 acquisition, viral load and disease progression 3 , followed by several publications investigating clinically correlated phenotypes in a largely overlapping set of HIV-positive individuals 1,4,5 .
CCL3L1 and HIV/AIDS susceptibility
Next, we tested whether CCL3L1 variation influences disease progression. We used both a quantitative measure of progression introduced previously 6 (consisting of measured or estimated time to CD4 + cell count <350 per mm 3 or initiation of antiretroviral therapy; Supplementary Methods) and a simple case-to-control comparison of progressors versus nonprogressors (defined as progression to CD4 + cell count <350 per mm 3 or antiretroviral therapy within 10 years since seroconversion versus no progression within 10 years). Finally, we tested for an effect of CCL3L1 low versus CCL3L1 high group assignment on these measures as well as on progression to AIDS 1987, AIDS 1993 or AIDS-related death using a Cox proportional hazards model. Neither CCL3L1 copy number nor CCL3L1 low versus CCL3L1 high genotype group assignment was associated with disease progression under any of these models Linear regression of HIV viral load at set point on CCL3L1 copy number showed no significant effect of CCL3L1 dose (European: r 2 = 0.0006, P = 0.14; African: r 2 = 0.0022, P = 0.27). (e,f) Relationship among CCL3L1 copy number, CCL3L1 mRNA expression and viral load at set point.
differences in input DNA amounts between cases and controls can lead to biased copy number estimates by the real-time PCR method used here, and, in fact, we found an apparently considerable association in the direction opposite to that previously reported 3 (with higher copy number among HIV + cases compared with controls) before diluting DNA samples into an appropriate range (Supplementary Table 2 ). Additionally, we compared the results of various assays (the real-time PCR-based assay used here and in the previous reports 1, 3, 4 and a recently published method based on the paralogue ratio test (PRT) 10, 11 ) and found that although the results were generally very highly correlated, for one comparison the association statistics from the two assays diverged markedly. Specifically, in a comparison of a small number of HIV-positive and HIV-negative samples from Malawi, copy number estimated by the PRT method showed a strong association with infection status, whereas the real-time PCR-based estimates showed no association; this discrepancy seems to be explained by systematic differences in DNA degradation between case and control samples, in which degradation or shearing of DNA leads to systematic overestimation of copy number by the PRT method specifically (Supplementary Table 3 ). Among HIV-positive individuals, we did not observe either assay method recording a signal of association for any HIV-related quantitative trait; these tests are both more statistically powerful than the case-to-control comparisons and far less sensitive to any 'batch effects' on the copy number estimation. Although both of the assays described here are liable to various types of systematic biases, we emphasize that differences between cohorts in the distribution of DNA concentrations are presumed to be far more likely, and perhaps expected, compared with differences in DNA storage or degradation, and thus the real-time PCR method will often be expected to produce a false positive association unless input DNA amounts are carefully considered. We therefore suggest that some of the previously reported associations may reflect differences in DNA quality or concentration that systematically increase or decrease the inferred number of copies of CCL3L1 in cases versus control samples.
(P > 0.1 for all tests) ( Table 1) . We then tested whether CCL3L1 copy number is associated with risk of HIV infection by comparing the copy number distributions in HIVinfected individuals compared with individuals who were judged to be unusually exposed to HIV but remain uninfected (called HSRN). Using samples from the MACS cohort, we compared 451 HIV-positive to 195 HRSN individuals. This comparison was well powered to detect effects of CCL3L1 copy number on risk of infection through mucosal exposure (the principal model of transmission in this cohort; Supplementary Table 1) . We found no association between infection status and either copy number (P = 0.53) or genotype risk group (P = 0.18) ( Table 1 ). In the same sample, CCR5∆32 homozygosity was strongly associated with reduced risk of infection (the CCR5∆32-homozygous genotype frequency was 4.9% in exposed uninfected versus 0% in infected individuals, P = 3.5 × 10 −6 ). Of note is the enrichment of CCR5∆32 homozygotes in the HRSN sample (4.9% versus an estimated 1% in unselected individuals of European descent) 9 , indicating that the effective exposure in the HRSN cohort was very high and therefore that this cohort should provide sufficient power to detect additional genetic risk factors of reasonable effect size. Notably, we also found no effect of CCL3L1 copy number on infection risk after stratifying according to CCR5∆32 genotype.
We investigated whether CCL3L1 copy number influences CCL3L1 messenger RNA expression in CD4 + T lymphocytes from 122 HIVpositive individuals who had not yet initiated antiretroviral therapy, using the Illumina WG-6 v3 expression array (Supplementary Methods), and found a strong and linear increase of CCL3L1 mRNA levels with copy number (r 2 = 0.23, P = 3.0 × 10 −8 , Fig. 1e ). In the same samples, however, CCL3L1 mRNA expression itself showed no correlation with HIV set point (r 2 = 0.003, P = 0.51, Fig. 1f ).
These observations raise the question of why earlier studies reported positive associations that we could not replicate here. As a possible explanation, we note that measurement of CCL3L1 copy number variation seems to be highly susceptible to systematic biases related to the preparation and quality of DNA samples. We observed that batch In summary, we find the absence of any substantial effect of CCL3L1 copy number variation on HIV-1 infection, viral load or disease progression. We do, however, show a highly significant (P = 3.0 × 10 -8 ) association between copy number variation and CCL3L1 mRNA levels, demonstrating that the assays are sufficiently accurate to detect the intermediate biological effects of copy number variation. Although there is some evidence that reduced expression of the CCR5 receptor may aid in viral control and delay progression to AIDS, there is less reason to believe that CCR5 inhibition is protective from infection without complete CCR5 blockade. Other groups have shown that CCL3L1 mRNA and MIP-1αP protein are expressed at relatively low levels compared with other CCR5 ligands, with measured serum concentrations of MIP-1αP protein well below its estimated half-maximal effective concentration, determined on the basis of ex vivo assays 7, 12 . Indeed, concentration increases to orders of magnitude higher than those reported in both healthy and HIV-infected individuals seem to be required to approach half-maximal occupancy by CCL3L1, whereas a reduction in receptor concentration would effectively multiply the affinity of all CCR5 ligands, including the much more abundant CCL5 (RANTES) and others in addition to MIP-1αP 7 . We should note that these arguments do not apply to the postulated effects of CCL3L1 that operate independently of direct CCR5 blockade, for example through effects on the expression of innate defense pathways. Such an explanation, however, might also be expected to drive correlations between CCL3L1 expression and viral control in infected individuals, which we did not observe (Fig. 1d) . We point out that a gold standard for copy number determination in this region is yet lacking and that the current techniques are likely to be influenced by other sources of error beyond the systematic ones described here. Despite progress in cataloging sequence and structural variation in the CCL3L1 region 13 , accurate assessment of the contribution of genetic variation in such a complex region will require the development of more accurate assay methods that provide information about not only gene copy number but also gene content. Finally, we emphasize that these results do not cast any doubt on efforts to develop CCR5 antagonists (that is, MIP-1αP analogs) as therapeutics for HIV prevention and treatment but merely argue that natural variation in CCL3L1 gene dose does not seem to have any major effects on the control of HIV-1.
All experiments were approved by the Duke University Institutional Review Board. Informed consent was obtained from all participating subjects.
To the Editor:
A selective advantage against infectious diseases such as HIV/AIDS is associated with differences in the genes relevant to immunity and virus replication. The CC chemokine receptor-5 (CCR5), the principal coreceptor for HIV, and its chemokine ligands, including CC chemokine ligand-3-like-1 (CCL3L1), influence the susceptibility of the CD4 + target cell to infection 1 . The CCL3L1 gene is one of several cytokine genes clustered in a region of segmental duplication on chromosome 17q12 (ref. 2) . The CCL3L1 gene copy number per diploid genome varies between people and among persons of various geographical ancestries [2] [3] [4] [5] ; some people have a partial CCL3L1 pseudogene as well 2 . Evidence has been presented that increased CCL3L1 gene copy numbers can have marked phenotypic consequences for HIV/AIDS pathogenesis as a result of altering gene dosage [3] [4] [5] . We have been unable to reproduce these findings using the same methods in a different cohort.
We conducted a population-based study of men enrolled in the Chicago component of the Multicenter AIDS Cohort Study (MACS, Supplementary Methods) to estimate the influence of the population-specific CCL3L1 gene copy number on the risk of HIV infection and/or disease progression and the robustness of immune recovery after the initiation of highly active antiretroviral therapy (HAART). We measured CCL3L1 gene copy number by real-time PCR assays 3 with modification. For each genomic DNA sample, we determined the CCL3L1 and CCR5 gene copy numbers in triplicate (Supplementary Methods). We validated standards constructed for absolute quantification of CCL3L1 gene copy number with sequential dilutions of A431 cell lysate that contains two copies of the CCR5 gene and two copies of the CCL3L1 gene per diploid genome 6 . The measured distribution of CCL3L1 gene copy numbers peaked near biologically interpretable integer values and was rounded to the nearest integer value in all calculations ( Supplementary  Fig. 1a,b) . The frequency distribution of CCL3L1 gene copy numbers varied across populations with median copy numbers of 2 (interquartile range (IQR) defined as the twenty-fifth to seventy-fifth percentiles, 2 to 3) in the sample of 740 European-American men, 4 (IQR 2 to 4) in the 53 white or black Hispanic-American men and 4 (IQR 3 to 6) in the 224 African-American men, similar to those reported by others [3] [4] [5] . The difference between the European-American and African-American men is highly significant (Mann-Whitney U test, P < 2.2 × 10 -16 ). The Hispanic-American men differed from both the European-American and the African-American men (Mann-Whitney U test, P = 1.49 × 10 -7 and P = 6.0 × 10 -4 , respectively), but there was little power to distinguish between the white and black Hispanic-American men.
To determine the influence of CCL3L1 gene copy number on the risk of acquiring HIV, we assessed the difference in the frequency distribution between HIV-infected (n = 580) and uninfected (n = 437) men. We randomly distributed the genomic DNA for these groups of men across and among the microtiter plates, and the sample values were reproducible between measurements. We found no evidence that the number of CCL3L1 gene copies is conditional on the HIV infection status within each geographic ancestral population (median 2 (IQR 2 to 3) for both groups in European-Americans, Mann-Whitney U test, P = 0.95; median 4.5 (IQR 3 to 6) in HIV-infected European American men compared to median 4 (IQR 3 to 5) in uninfected African American men, P = 0.11) (Supplementary Fig. 1 ). The HIV infection status did not differ significantly in men carrying CCL3L1 gene copy numbers lower than the population-specific median (95% confidence interval (95% CI) on odds ratio = 0.89 [0.66, 1.19] Fisher's exact P = 0.43) [7] [8] [9] . Fitting a generalized linear model, including a score indicating risk of infection based on behavior 10 and CCL3L1 gene copy number relative to each population-specific median (designated CCL3L1 high and CCL3L1 low ), only the risk score is highly significant (P = 2 × 10 -8 ); CCL3L1 gene copy number is not (P = 0.87).
To test for association between CCL3L1 gene copy number and the risk of progression to AIDS, we graphically assessed the development of an AIDS-defining illness before 1996 (the pre-HAART era) by Kaplan-Meier survival curves (Fig. 1) . Although the lines overlapped, we observed a separation of the curves later in time (Fig. 1) . Consequently, we examined the association between CCL3L1 gene copy number and very slow progression to AIDS. We classified men according to whether AIDS occurred within 9 years of infection (that is, the expected median progression time observed before 1996) or whether they remained free of AIDS for at least 12 years in the absence of HAART. The 46 EuropeanAmerican men with incident infection who developed AIDS within 9 years (typical progressors) had a lower CCL3L1 gene copy number than the 88 European-American men who remained free of AIDS for at least 12 years (slow progressors; Supplementary Fig. 2 ). Whereas both groups of men had a median CCL3L1 gene copy number of 2, 75% of the typical progressors had 2 CCL3L1 gene copies or lower, and 75% of the slow progressors had two CCL3L1 gene copies or higher (Mann-Whitney U test, P = 0.023; Supplementary Fig. 2 ). This finding is consistent with a previous report 3 and may indicate a real effect of CCL3L1 gene copy number variation on HIV disease progression or a false-positive association signal that arises from the aspects of analysis common to both studies, such as rounding the estimates derived from real-time PCR assays to determine CCL3L1 gene copy numbers to the closest integer.
In HIV-infected men, we found no relationship between the CCL3L1 gene copy number and the level of HIV RNA in plasma after resolution of acute infection (Kendall's rank correlation P = 0.5 and P = 0.6 in European-American men and African-American men, respectively) or the CD4 + T cell slope (Kendall's rank correlation P = 0.08 and P = 0.35 in European-American men and African-American men, respectively). When we dichotomized the CCL3L1 gene copy number at the median, neither the CD4 + T cell slope (median -52.2 cells per µl per month (IQR -106 to -21) against median -51.5 cells per µl per month (IQR -96 to -23); Mann-Whitney U test, P = 0.88) nor the level of HIV RNA in plasma at set point (median 16,310 copies per ml (IQR 3,446 to 38,490) against median 16,810 copies per ml (IQR 4,364 to 41,330); Mann-Whitney U test, P = 0.33) differed between the men possessing CCL3L1 gene copy numbers lower than the median compared to the rest of the population.
We next measured the size and the significance of the interaction between the CCL3L1 gene copy number and the CCR5 ∆32 proteininactivating deletion allele (CCR5∆32). Notably, CCR5∆32 and the seven single nucleotide polymorphisms within the CCR5 human haplogroup E (HHE) that influences HIV/AIDS susceptibility (that is, the principal detrimental CCR5 genotype previously reported 3 ) are in strong linkage disequilibrium with each other (reported previously for men from the MACS 11 ). The men were stratified into groups on the basis of whether they possessed a CCL3L1 gene copy number higher than or equal to or lower than the population-specific median (CCL3L1 high or CCL3L1 low , respectively) and the presence or absence of CCR5∆32 (CCR5 wild-type or CCR5 ∆32 , not distinguishing between the CCR5 ∆32/∆32 and CCR5 ∆32/ wild-type genotypes) ( Table 1) . We analyzed the influence of the CCL3L1-CCR5 genotype on HIV infection by means of Cox proportional hazards models after adjusting for the behavioral risk score 10 . In this analysis, we did not find an HIV infection-influencing effect of CCR5∆32 (likelihood ratio = 0.18; hazard ratio = 0.75) or CCL3L1 low (likelihood ratio = 0.42; hazard ratio = 0.83). This conclusion remained unchanged when we performed the Cox proportional hazards model analysis with an interaction variable.
Although the CCR5 ∆32/∆32 genotype was highly enriched among the uninfected men (95% CI on odds ratio [2.25, 672 .19]; Fisher's exact, P = 0.0005 for all men and P = 0.007 for European-American men), Figure 1 HIV diseaseinfluencing effect associated with number of CCL3L1 gene copies during the pre-HAART era. Kaplan-Meier survival curves are shown for European-American men who posses more than or less than or equal to the populationspecific median number of CCL3L1 copies (two copies). Compared with possession of more than two CCL3L1 gene copies, men possessing less than or equal to two CCL3L1 gene copies had a higher risk of AIDS (13 of 124 European-American men compared with 40 of 272 European-American men over the study period, respectively), but the difference is not significant. Men who became infected with HIV during follow-up were at risk for event from the time of their estimated infection, defined as the midpoint between their last HIV antibody-negative and first HIV antibody-positive visits. Men who were infected with HIV at the time they entered the study were treated as censored observations; that is, the time of infection was unknown. Table 1 ). The median or mean level of viral RNA in plasma at set point is about half in the men possessing the CCR5 ∆32/wild-type genotype (median 9,520 copies per ml (IQR 1,820 to 28,520)) compared to those men possessing the CCR5 wild-type genotype (median 17,310 copies per ml (IQR 4,647 to 45,740); Mann-Whitney U test, P = 0.02). When compared to the median, the CCL3L1 gene copy number had no effect within either of these groups. In particular, among the CCR5 ∆32/wild-type -CCL3L1 low and CCR5 ∆32/wild-type -CCL3L1 high groups, the median level of HIV RNA in plasma at set point was 8,109 copies per ml (IQR 1,208 to 24,020) and 10,180 copies per ml (IQR 1,852-30,520), respectively (Mann-Whitney U test, P = 0.38). Similarly, among the CCR5 wild-type -CCL3L1 low and CCR5 wild-type -CCL3L1 high groups, the median level of HIV RNA in plasma at set point was 15,700 copies per ml (IQR 3,495 to 39,760) and 17,660 copies per ml (IQR 4,964 to 480,400), respectively (MannWhitney U test, P = 0.25). Although CCR5∆32 has an effect on the level of HIV RNA at set point, the effect is independent of the CCL3L1 gene copy number. The CD4 + T cell slope did not differ between the CCR5 ∆32/wildtype (median -56 cells per µl per month (IQR -101 to -24)) and the CCR5 wild-type (median -52 cells per µl per month (IQR -97 to -23]) groups (Mann-Whitney U test, P = 0.62), the CCR5 ∆32/wild-type -CCL3L-1 low (median -43 cells per µl per month (IQR -81 to -5)) and CCR5 ∆32/ wild-type -CCL3L1 high (median -58 cells per µl per month (IQR -100 to -32)) groups (Mann-Whitney U test, P = 0.27) nor between CCR5 wildtype -CCL3L1 low (median -55 cells per µl per month (IQR -108 to -24) and CCR5 wild-type -CCL3L1 high (median -51 cells per µl per month (IQR -97 to -23)) groups (Mann-Whitney U test, P = 0.49). We obtained similar results when restricting the analysis to the European-American subpopulation; specifically, we found a lower level of HIV RNA at set point in the CCR5 ∆32/wild-type (median 8,994 copies per ml (1,736 to 28,190) ) than the CCR5 wild-type (median 18,380 copies per ml (5,350 to 48,280)) groups (Mann-Whitney U test, P = 0.01) and no difference in the CD4 + T cell slope between the CCR5 ∆32/wild-type (median -57 cells per µl per month (IQR, -96 to -30)) and CCR5 wild-type (median -57 cells per µl per month (IQR, -104 to -29)) groups (Mann-Whitney U test, P = 0.78). In addition, there was no effect of CCL3L1 gene copy number on either of these outcomes when restricted to the CCR5 wild-type (Kendall rank correlation, P = 0.38 for the set point and P = 0.04 for the slope) and CCR5 ∆32/wild-type (Kendall rank correlation, P = 0.43 for the set point and P = 0.99 for the slope) grouping.
We next tested whether the CCL3L1-CCR5 genotype influenced the extent of reconstitution of the CD4 + T cell count during HAART 4 . We used the square root of the CD4 + T cell count as the outcome in a repeated-measures regression model, accounting for the correlated measurements contributed by the same person over time. The model included the CD4 + T cell count and the level of HIV RNA in plasma in the year before the start of HAART with an indicator for whether clinical AIDS had been diagnosed before its initiation. We stratified the model by the CD4 + T cell count (that is, <350 cells per µl and >350 cells per µl) to determine whether the stage of HIV disease at the time of initiation of HAART modified the effect of the CCL3L1-CCR5 genotype on immune reconstitution 4 .
Using general estimating equations (Supplementary Methods), the mean rate of change in the CD4 + T cell count for European American men after initiation of HAART showed no distinction between the CCL3L1 high or CCL3L1 low group either within the first 2 years after the start of HAART (coefficient 0.04 per year per CCL3L1 gene copy number with s.e.m. 0.41), or at any time thereafter (coefficient -0.02 per year per CCL3L1 gene copy number with s.e.m. 0.07), whether or not the CD4 + T cell count was stratified at its initiation. There was no difference in the recovery rate for the CD4 + T cell count indexed from the time of initiation of HAART between the low-risk (CCL3L1 high -CCR5 ∆32/wild-type ; mean -0.2 cells per µl per month, s.e.m. 0.6), medium risk (CCL3L1 low -CCR5 ∆32/wild-type or CCL3L1 high -CCR5 wild-type ; mean 0.1 cells per µl per month, s.e.m. 0.4), and high-risk (CCL3L1 low -CCR5 wild-type ; mean -0.1 cells per µl per month, s.e.m. 1.0) groups. These data confirm the previously reported lack of association between CCR5 ∆32/wild-type and the CD4 + T cell count after initiation of HAART 12 .
Our findings do not support a relationship between the populationspecific CCL3L1 gene copy number and HIV/AIDS susceptibility or the response to HAART as previously reported 3, 4 , even though we had a similar population, used the same method for determining the CCL3L1 gene copy number, used CCR5∆32 as a proxy for the CCR5 promoter polymorphisms 11 and used a study powered to detect the postulated effect (for example, a 62% power to observe the difference of 1 cell per µl per month between the high-and medium-risk groups at P = 0.1). Of note, three previous studies [3] [4] [5] determined the CCL3L1 gene copy number in the same HIV-infected (n = 1,127) and uninfected (n = 1,105) people (that is, individuals enrolled in the Wilford Hall Medical Center Cohort, a component of the United States Military Tri-Service AIDS Clinical Consortium Natural History Cohort Study, with the addition of an uninfected comparison group (n = 1,274) and HIV-infected and uninfected Argentinean children (n = 802) 3 and HIV-infected people enrolled in the Acute Infection and Early Disease Program 4,5 (n = 315 and n = 55, respectively)). Although we confirm The totals also include 52 men with undetermined CCR5 genotype. The number of CCL3L1 gene copies is higher than or equal to or lower than the population-specific median (that is, CCL3L1 high and CCL3L1 low , respectively). Only European-American men possessing CCR5 ∆32/∆32 or CCR5 wild-type alleles had a significantly different risk for acquiring HIV (Fisher's exact test, P = 0.007 for association between CCR5 genotype and HIV infection status).
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Copy number variants (CNVs) are duplicated or deleted segments of the genome that vary in size from a few bases to several kilobases and comprise a substantial proportion of normal genomic variation 1 . The role of population-wide CNVs in disease has only recently come under investigation 2, 3 . The gene encoding the chemokine (C-C) motif receptor CCR5, CCR5, on chromosome 3p21, has been associated with resistance to HIV-1 infection 2 . One of its ligands, CCL3L1, is encoded by a gene that lies in a CNV on chromosome 17q12 (ref. 4) , which includes another CCR5 ligand, CCL4L1 (Supplementary Fig. 1) , both of which have been reported to be associated with HIV-1/AIDS susceptibility 2, 5, 6 . CCR5 is associated with type 1 diabetes 7 , and hence we hypothesized that CCL3L1 is also associated with type 1 diabetes.
A reliable method for determining copy number at the 17q12 locus is required, as not only has the region been implicated in HIV-1/AIDS susceptibility, but also has been reported to influence disease progression with and without antiretroviral therapy 8, 9 and has been suggested as an informative approach to optimizing the design and evaluation of HIV-1 vaccine trials and prevention programs 10 . Quantitative real-time PCR (qPCR) is considered the 'gold standard' method for assessing copy number at individual CNV loci and was employed by the original CCL3L1 in HIV-1/AIDS study 2 as well as by subsequent studies of this CNV 11 . However, the CCL3L1 association with HIV-1 has not been independently replicated, with all reported positive associations originating from almost the same case sample set and control sample set 12 . Consequently, there may be experimental biases in the current qPCR CCL3L1 assay and its scoring.
In type 1 diabetes the median effect of susceptibility loci is below an odds ratio of 1.5 (ref. 13) , so thousands of samples are required to test for association, which is also the case for most other complex diseases. Hence, the CCL3L1 assay has to work efficiently and accurately in thousands of samples. We compared two methods of obtaining CCL3L1 copy number, the paralogue ratio test (PRT) 14 , and qPCR 2 . PRT and qPCR rely on comparing the signal from the CNV against that from a reference locus and obtaining the ratio. If the reference has two copies, then a ratio of 1:1 denotes two copies of the CNV (assuming equal PCR efficiencies for both reactions). PRT uses a locus paralogous to the CNV with invariant copy number as the reference 14 . For the CCL3L1 region, we used three PRT assays with CNVs CCL3L1 and CCL4L1 and a long terminal repeat (LTR) located between them and paralogous loci CCL3 and CCL4 and a LTR on chromosome 10q22, respectively. We scored these ratios to give integer copy numbers.
We studied DNA samples from 5,771 British individuals with type 1 diabetes and 6,854 geographically matched controls for CCL3L1 variation using qPCR and PRT assays (Supplementary Methods). Owing to small, but potentially crucial, variations in PCR efficiency, the ratios of assay product formed a distribution around the whole copy number (Fig. 1) . With PRT, discrete clusters were distinguishable for the ratios from both CCL4L1 and the nearby LTR, whereas clusters overlapped for CCL3L1 (Fig. 1a-f ). This could be the result of sequence-specific DNAbound protein interfering with the PCRs for CCL3L1. Differences in the DNA extraction methods for case and control DNA may have left different amounts of DNA-bound protein, resulting in differential cluster quality. In contrast to the LTR, both the CCL3L1 and CCL4L1 assay ratios were not centered on integer values but were shifted toward lower values. In controls, for example, one copy of CCL3L1 was centered on 0.8, two copies were centered on 1.6 and three copies were centered on 2.3 (Fig. 1b) . Having examined the distributions of the assay ratios, we assigned integer copy numbers using two methods; one was k-means clustering and the other was rounding the PRT data to the nearest integer (Supplementary Methods and Supplementary Discussion). The original HIV/AIDS study used rounding for their qPCR assays 2 .
Except in highly stratified populations, deviation from HardyWeinberg equilibrium (HWE) provides a useful indicator of genotyping error. Therefore, we developed a statistical test for HWE with multiallelic CNVs (Supplementary Methods). In controls, CCL3L1 was in HWE for the k-means PRT data but not for the rounded PRT data (Supplementary Table 1) , reflecting the inappropriateness of rounding in this case. Both CCL4L1 and the LTR were in HWE in controls ( Table 1 and Supplementary Tables 1 and 2) . As the k-means clustered data for each assay individually and averaged across assays were in HWE, we tested them for association with type 1 diabetes using a logistic regression
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model, with disease status as the outcome variable and copy number as the independent variable (Supplementary Methods). We found no convincing evidence of association (P > 0.05; Table 1, Supplementary Tables 1 and  2 and Supplementary Results). The CCL3L1 rounded data showed evidence of association with type 1 diabetes (P = 8 × 10 −11 ), but the deviation from HWE suggests that this was false and attributable to genotyping error. We also obtained evidence of association with the rounded data at CCL4L1 (P = 0.0002), owing to an excess of two copies at CCL4L1. The majority of the three-copy cluster lay between 2.0 and 2.5 and so was incorrectly scored as two copies when rounded (Fig. 1c,d) . Therefore, this association was an artifact of the method of assigning whole copy number (which was rounding) and, consequently, is likely to be false. We concluded that the LTR assay was the most robust of the three assays because the LTR ratios clustered well around integer copy numbers and so could be assigned by rounding or k-means, and the assay gave consistent results for the replicated quality control samples. Consequently, we tested the LTR for interaction with the CCR5∆32 allele in type 1 diabetes (Supplementary Methods), as combinations of CCR5-CCL3L1 genotypes have been reported to be associated with HIV-1/AIDS risk and progression 2,9 . We did not find evidence of a statistical interaction between the associations of CCR5 and CCL3L1 with type 1 diabetes (P = 0.29).
The distribution of ratios obtained by qPCR for CCL3L1 in cases and controls was shifted right toward higher than integer copy numbers (Fig. 1g,h) . We used k-means clustering (Supplementary Methods) and rounding to assign integer copy number. With both methods of assigning copy number, the CCL3L1 data from qPCR deviated from HWE in controls, owing to a lack of '0' copy numbers, and a rightward shift in the copy number distribution (Supplementary Table 3) . There was evidence for strong associations of CCL3L1 with type 1 diabetes (P = 7 × 10 −34 (k-means) and P = 3 × 10 −7 (rounding)), which, in light of the HWE tests and our PRT results, we regard as artifacts.
For qPCR, we used a standard curve on each plate to standardize the concentration of DNA between CNV and reference reactions within a plate, which introduced plate-to-plate variation. Standard curves are not required for PRT, which has reference and CNV reactions in the same well. As cases and controls were dispensed onto separate plates, the statistical test for association may have actually detected plate-to-plate variation and not type 1 diabetes association. Because we had so many plates (105), we were able to estimate the qPCR plate-to-plate variation (6% in controls and 2% in cases) to correct the association test. We reduced the apparent evidence of type 1 diabetes association, P = 7 × 10 −9 (k-means; Table   0 1) and P = 0.00019 (rounding; Supplementary Table 3 ). The remaining evidence of association may be attributable to shifts in copy number distribution, caused by unpredictable interactions between the assay and the differential quality and composition of DNA from several sources, leading to HWE deviation in the controls but not the cases 15 (Supplementary Discussion). These results not only show the importance of testing for HWE but also of allowing for plate effects in the analysis. We recommend arraying case and control samples onto the same plates. 5,121 samples were common to the PRT and qPCR experiments. Using the LTR as the most accurately scored measure of CCL3L1 for the PRT method and the k-means clustered data for the qPCR assay, we found that 64% were consistent between the two methods, with 25% having one additional copy of CCL3L1 with qPCR as compared to with PRT. Nine percent of the data had between two and five additional copies of CCL3L1 obtained using qPCR compared to PRT. Just 2% of the data had one or two copies more of CCL3L1 as measured by PRT than by qPCR. The qPCR assay also showed a general trend toward higher copy numbers compared to the other two PRT assays; a shift that may be an artifact of the qPCR primers also binding a CCL3L1 pseudogene, CCL3L2, as well as CCL3L1 (refs. 2,4,14) ( Supplementary Fig. 1 and Supplementary Discussion).
To our knowledge, this is the first report where CCL3L1 copy number has been estimated in such a large sample set using both qPCR and PRT. The PRT LTR assay copy number showed good clustering, with no difference in distribution between type 1 diabetes cases and controls, suggesting that the primers designed for this locus are highly specific and robust to variations in source of DNA. PRT also avoids potential error in scoring zero copy numbers. We recommend rounding the data if the assay ratios cluster distinctly around integers and using k-means clustering otherwise. qPCR can be used to assay CCL3L1 in large well-powered sample sets if appropriate quality control measures are implemented. The distribution of copy number and its dependence on DNA source should be examined statistically, and an appropriate method of assigning copy number should be adopted for each DNA source. Tests for deviation from HWE must be performed, and any detected deviations should be resolved. If they cannot be resolved, an assay such as PRT should be used instead. In small sample sets (for example, n ≤ 500), even in the absence of deviations from HWE, any associations should be treated with some skepticism, owing to the limited power to detect deviations from HWE (Supplementary Results).
Finally, we note that there is marked variation in CCL3L1 copy number according to ethnic group, which others have reported 2 Table 4 ). We genotyped 95 African Yoruban samples in duplicate using the LTR PRT assay. Our data was highly reproducible (correlation coefficient > 0.99; Supplementary Fig. 2) . The CNVs were between 2.0 and 8.0 (Supplementary Table 4) , with a mean copy number of 4.3. Hence, any inadvertent admixture, as seems possible upon detailed evaluation of the original CCL3L1 in HIV-1/AIDS study in which European Americans had different CCL3L1 copy numbers than Hispanic Americans 2 , combined with the copy number distribution shifts interacting with DNA source and the error-prone copy number scoring (that is, rounding) described here, could lead to apparently highly significant disease associations.
(Supplementary
We collected all DNA samples with approval from the Cambridgeshire 2 Research Ethics Committee, and we obtained written consent from all individuals or from the parents of individuals who were too young to consent.
Note: Supplementary information is available on the Nature Medicine website.

He et al. reply:
We read with interest the three correspondences 1-3 that are directly or indirectly related to our previous publication in Nature Medicine 4 . Because of methodological concerns with their own C-C chemokine ligand-3-like-1 (CCL3L1) gene quantitative PCR (qPCR) assay, Urban et al. 1 assume that similar limitations apply to the assay that we and others have used and, by extension, infer that all of the several reported associations for CCL3L1 copy number with HIV/AIDS suceptibility (Supplementary Table 1 ) are spurious. We tested the validity of this assumption. Notwithstanding their statement that they "assayed for CCL3L1 copy number using a previously described method" (described in ref. 5 here), Urban et al. 1 made two major modifications to our qPCR assay, which we show adversely affect assay performance. Although they used the same probe sequences, instead of using tetramethylrhodamine (TAMRA) as the quencher, they used minor groove binder (MGB), a change that raises the melting temperature of the probe 8 º C higher than the optimal temperature (Supplementary Table 2) . Urban et al. 1 also raise the concern that our assay is confounded, because they observed that CCL3L1 gene copy number (GCN) differed with the co r r e s p o n d e n c e quality and the amount of input DNA. Our published protocol specifically recommended a fixed amount of high-quality input DNA between 2 and 10 ng 5 , and, consequently, we used qPCR standard curves comprising twofold dilutions from 25 to 0.78 ng. By contrast, Urban et al. 1 used variable amounts of input DNA (up to 100 ng) and constructed standard curves of tenfold dilutions from 100 ng to 1 pg.
The TAMRA-based assay that was initially used to estimate CCL3L1 GCN 6 was, as reported previously 5 , refined by us until its performance met rigorous quality control measures similar to those shown in Figure  1 . Here we concurrently evaluated the performances of the MGB and TAMRA-based assays. The standard curves for the target (CCL3L1) and normalizer (HBB; encoding human β-globin B) genes were parallel with the TAMRA assay, whereas this was not the case for the MGB assay (Fig.  1a) . Consequently, the inferred amplification efficiencies for CCL3L1 and HBB were more divergent for the MGB assay than for the TAMRA assay (Fig. 1a) . Compared with the MGB assay, the TAMRA assay had better intra-assay reproducibility (Fig. 1b) . The unrounded CCL3L1 GCN estimates in a cell line authenticated to have two copies (Fig. 1c) and in 628 human DNA samples (Fig. 1d) were significantly closer to the nearest integer with the TAMRA assay than with the MGB assay. In agreement with the findings of Urban et al. 1 , the CCL3L1 GCN with the MGB assay differs with varying input DNA (Fig. 1e) . However, this sensitivity to input DNA is not a characteristic of the TAMRA assay that we used (Fig. 1e) . Table 5 ). (h) Bubble plot showing the disagreement between rounded CCL3L1 GCN estimates made by the TAMRA (y axis) and MGB (x axis) assays. Each bubble is centered over the intersection of the specific discrepant GCN values, and the size of the bubble is proportional to the number of discrepant samples at each intersection. The angled line indicates rounded CCL3L1 GCNs that were identical for both assays, and, for ease of visualization, these samples are not depicted with bubbles (351 of 628 samples (56%)). The MGB assay underestimated in 62 (10%) and overestimated in 215 (34%) samples the CCL3L1 GCN compared to the CCL3L1 GCN from the TAMRA assay (Supplementary Table 6 ). Bubble 2/1, two copies estimated by TAMRA assay, one copy by MGB assay.
We previously showed the internal validity of the CCL3L1 GCN obtained by the TAMRA assay 7 . CCL3L1 GCN reflects the sum of the GCNs of three separate CCL3L genes (CCL3L1, CCL3L2 and CCL3L3; Fig. 1f) . We quantified the GCNs of these three CCL3Ls with two separate assays, one specific for CCL3L1 and CCL3L3 GCN and the other for CCL3L2 GCN (Fig. 1f) 7 . Thus, a 'total' CCL3L1 GCN determination has internal validity if it approximates the sum of the GCNs of the individual CCL3Ls 7 . This, we found, was much more consistently the case with the TAMRA assay than with the MGB assay (Fig. 1g) . Consequently, the concordance between the rounded (nearest integer) CCL3L1 and CCL3L3 GCN plus CCL3L2 GCN and 'total' CCL3L1 GCN was 94% with the TAMRA assay, whereas it was 60% with the MGB assay (Fig. 1g) . In keeping with these divergent results, we observed discrepancies between the TAMRA and MGB assays in the rounded CCL3L1 GCN in 44% of 628 samples. The impact of these misclassifications was amplified by the fact that, relative to the TAMRA assay, the MGB assay underestimated GCN at lower values but overestimated it at higher GCN values (Fig. 1h) . Given the performance characteristics of the two assays (Fig. 1a-g ), it is reasonable to conclude that the true GCN corresponds better to the TAMRA assay value. Notably, among the 177 samples classified by TAMRA as having two copies, the MGB assay underestimated 37 samples as bearing one copy (Fig. 1h) , an error that may obscure the association of low copy numbers with HIV/ AIDS susceptibility. For example, we previously found that a low copy number of CCL3L1 (assayed by TAMRA probe) associated with increased HIV/AIDS susceptibility in 298 Ukrainian children exposed perinatally to HIV-1 7 ; affirming this, we observed similar associations for CCL4L1 GCN (determined by a separate assay) 7 , a predictable association because, in this study population, the copy numbers of CCL3L1 and CCL4L1 are highly correlated 7 . In contrast, when we repeated the genotyping of CCL3L1 GCN in this cohort with the MGB-based assay, we found that CCL3L1 GCN estimated by the MGB assay failed to identify the associations of CCL3L1 GCN with the risk of acquiring HIV infection (odds ratio, 0.94; 95% confidence interval, 0.56-1.56; P = 0.80) and rate of progression to AIDS (relative hazard, 1.41; 95% confidence interval, 0.79-2.51; P = 0.24). Thus, we surmise that the use of the MGB assay and variable input DNA together may have compromised the results of the association studies by Urban et al. 1 Bhattacharya et al. 2 Table 2 ). The predicted melting temperature for their Quencher Series 7 (QSY7)-based probe is 8 º C lower than the optimal temperature. Although we have had insufficient time since receiving this correspondence to make direct comparisons between the QSY7 assay and the TAMRA assay, conceivably this modification may affect assay performance. Moreover, Bhattacharya et al. 2 have not adequately accounted for genetic-epidemiological factors pertinent to the full interpretation of their results. First, in subjects followed from the early stages of HIV infection, we found that, because a high CCL3L1 GCN associated with a slower rate of progression to AIDS and death, at a population level there was a gradual enrichment over time of HIV-positive subjects with a protective high CCL3L1 GCN 5 . Consequently, ~7 years after seroconversion, the prevalence of CCL3L1 GCN in surviving HIV-positive individuals approaches that of HIV-negative individuals 5 . Hence, because Bhattacharya et al. 2 studied mostly seroprevalent subjects (~78%), it is predictable that they found similar CCL3L1 GCN distributions in HIV-infected and uninfected subjects. Second, during the study period (12 years) there were only 53 AIDS events, representing 13% of their subjects (n = 396). By contrast, during a comparable time period, AIDS developed in ~40% of the 1,132 adult subjects we studied 5 . Given the limited AIDS events and small sample size, it is not surprising that strong associations between CCL3L1 GCN and AIDS were not detected. Nevertheless, their data confirm our results showing that long-term nonprogressors are enriched for a high CCL3L1 GCN 8 . Third, Bhattacharya et al. 2 failed to detect an association between CCL3L1 GCN or conjoint genotypes of CCL3L1 GCN and the CCR5∆32 allele with highly active antiretroviral therapy (HAART) responses. They suggested that the observed lack of association of CCL3L1 GCN with recovery of CD4 + T cell counts during HAART was robust, because they found that CCR5∆32 heterozygosity also did not associate with beneficial CD4 + T cell count responses in their cohort 2 . However, contrary to their results, several studies have shown that CCR5∆32 heterozygosity is associated with improved CD4 + T cell and viral load responses during HAART [9] [10] [11] [12] [13] , including work from the Multicenter AIDS Cohort Study cohort, from which their study subjects were derived 2 . Thus, their failure to find an Table 7) , respectively, for the pair-wise comparisons of the correlations. association between CCR5∆32 heterozygosity and HAART responses does not confer or imply validity for the lack of an association for CCL3L1 GCN with CD4 + T cell count responses, as both of these findings reported by Bhattacharya et al. 2 may represent false negatives.
also modified the qPCR assay (Supplementary
Notably, Fields et al. 3 , on the basis of their results using a paralogous ratio test (PRT) and qPCR assay for CCL3L1 GCN conducted in subjects with diabetes, suggest that our observed associations of CCL3L1 GCN with HIV/AIDS are suspect. However, their PRT assay quantifies two CCL3L genes (CCL3L1 and CCL3L3), whereas the qPCR we used for association studies quantifies three 5, 7 (Fig. 1f) . This precludes any direct comparison of the CCL3L1 GCN estimates obtained by PRT versus qPCR and limits inferences of association studies because it does not account for the possible contributions to disease susceptibility of CCL3L2, which, contrary to previous assumptions, does not seem to be a pseudogene 7 .
Because Fields et al. 3 found that the CCL3L1 GCN departed from Hardy-Weinberg equilibrium, they infer that our qPCR assay does not provide robust GCN estimates. This inference based on Hardy-Weinberg estimates oversimplifies the analysis of a highly complex genomic region. Their Hardy-Weinberg estimates would be valid if the copy number variations (CNVs) of the individual CCL3L genes were both duplicated and distributed randomly on each chromosome, permitting accurate computation of copies per chromosome. However, recent studies 14, 15 and the following four data sets suggest otherwise. First, we derived CCL3L1 GCN data from 655 parent-child trios and found that it is very difficult to predict the chromosome phase of CCL3L1 GCN, even in individuals with two copies but especially in those with >2 copies (Fig. 2a-d) . Second, consistent with this observation, using the expectation maximization algorithm described by Fields et al. 3 , we found that Hardy-Weinberg estimates in 991 normal donors departed from equilibrium only when they were computed for a CCL3L1 GCN of >2 but not ≤2 (Supplementary Note). Third, among 655 parent-child trios, we identified 62 trios for whom the CCL3L1 GCN phase of each family member could be resolved. However, the expectation maximization algorithm misclassified the CCL3L1 GCN phase in 13% of these 186 subjects. For example, 20 individuals with two gene copies of CCL3L1 on one chromosome and zero copies on the other chromosome were misclassified as having one gene copy of CCL3L1 on each chromosome (Supplementary Table 3) .
Finally, underscoring that the CCL3L-CCL4L region is unlikely to be a single duplicon, there are fewer CCL4L than CCL3L copies 6, 7, 14 , and correlations of the GCN among CCL3Ls and CCL4Ls vary significantly among populations represented in the Human Genome Diversity Cell Line Panel (HGDP)-CEPH samples (Fig. 2e) . In some populations, there is an inverse correlation between CCL4L1 and CCL4L2 GCNs (Fig. 2e) . Consistent with this unbalanced distribution of CCL3L and CCL4L genes, high-resolution CNV data also show that the CCL3L-CCL4L region shows extensive architectural complexity, with smaller CNVs embedded within larger ones and with interindividual variation in breakpoints 15 . This degree of complexity is also highlighted by recent sequence data showing that the most extreme copy number variation corresponds to genes that are embedded within segmental duplications 16 , such as the CCL3L-CCL4L genes (Fig. 1f) 7, 17 . Thus, accounting for this genomic complexity, including CCL3L2 GCN, is crucial for full interpretation of association studies, because the combinatorial content of CCL3L and CCL4L GCNs influences HIV/AIDS susceptibility 7, 14 . On a technical note, there was a very high correlation between the rounded versus the k-mean clustered CCL3L1 GCN estimates (Supplementary Note), making it unlikely that the method used to discretize GCN confounded our association studies.
Contrary to the assertions in these three correspondences [1] [2] [3] , the association of CCL3L1 GCN with HIV/AIDS susceptibility has been confirmed by us and others in multiple cohorts and also in nonhuman primates 17, 18 (Supplementary Table 1) . Moreover, there is a highly plausible biological and experimental basis for these associations: CCL3L1 is the most potent HIV-suppressive chemokine, and a low CCL3L1 GCN associates with lower chemokine expression, reduced cell-mediated immunity, lower HIV-specific Gag responses and higher viral loads (Supplementary Table 1) . Furthermore, concordant associations of CCL3L1-CCR5 genotypes with immune reconstitution were detected among subjects who received HAART at three stages of HIV disease: acute, early and chronic infection 4 . Notably, among subjects who received HAART during chronic infection, consistent associations for CCL3L1-CCR5 genotypes were observed for two phenotypic endpoints, namely, recovery of CD4 + T cell counts 4 and CD4 + T cell function 8 . We surmise that methodological and epidemiological confounders and failure to account for the genomic complexity of the CCL3L-CCL4L locus underlie the lack of associations reported by these correspondences [1] [2] [3] .
The human DNA samples used were in accordance with the Institutional Review Boards of University of Texas Health Science Center and University of California at San Diego.
Note: Supplementary information is available on the Nature Medicine website.
